147 related articles for article (PubMed ID: 28543368)
1. Primary signet-ring cell/histiocytoid carcinoma of the eyelid expressing androgen receptors and treated with bicalutamide.
Sakamoto K; Ito T; Tanioka F; Fukamizu H; Tokura Y
J Dermatol; 2017 Sep; 44(9):e230-e231. PubMed ID: 28543368
[No Abstract] [Full Text] [Related]
2. Complete Response of Metastatic Androgen Receptor-Positive Breast Cancer to Bicalutamide: Case Report and Review of the Literature.
Arce-Salinas C; Riesco-Martinez MC; Hanna W; Bedard P; Warner E
J Clin Oncol; 2016 Feb; 34(4):e21-4. PubMed ID: 24888812
[No Abstract] [Full Text] [Related]
3. Primary signet-ring cell/histiocytoid carcinoma of the eyelid: a clinicopathologic study of 5 cases and review of the literature.
Requena L; Prieto VG; Requena C; Sarasa JL; Manzano R; Seco M; Rütten A; Kazakov DV; Cerroni L; Kutzner H
Am J Surg Pathol; 2011 Mar; 35(3):378-91. PubMed ID: 21317710
[TBL] [Abstract][Full Text] [Related]
4. [Bicalutamide].
Taéron C
Rev Infirm; 2010 Mar; (158):47-9. PubMed ID: 20383962
[No Abstract] [Full Text] [Related]
5. [Bicalutamide].
Kotake T
Nihon Rinsho; 2000 Jul; 58 Suppl():216-22. PubMed ID: 11022717
[No Abstract] [Full Text] [Related]
6. Bicalutamide with radiotherapy for prostate cancer.
Brower V
Lancet Oncol; 2017 Mar; 18(3):e141. PubMed ID: 28190764
[No Abstract] [Full Text] [Related]
7. Editorial comment to Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: clinical application and validation.
Yoshida T
Int J Urol; 2013 Jul; 20(7):714-5. PubMed ID: 23216631
[No Abstract] [Full Text] [Related]
8. Oral bicalutamide for female pattern hair loss: A pilot study.
Fernandez-Nieto D; Saceda-Corralo D; Rodrigues-Barata R; Hermosa-Gelbard A; Moreno-Arrones O; Jimenez-Cauhe J; Ortega-Quijano D; Vano-Galvan S
Dermatol Ther; 2019 Nov; 32(6):e13096. PubMed ID: 31579984
[No Abstract] [Full Text] [Related]
9. Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines.
Koukourakis MI; Kakouratos C; Kalamida D; Mitrakas A; Pouliliou S; Xanthopoulou E; Papadopoulou E; Fasoulaki V; Giatromanolaki A
Anticancer Drugs; 2018 Apr; 29(4):323-333. PubMed ID: 29381490
[TBL] [Abstract][Full Text] [Related]
10. Photosensitive drug eruption induced by bicalutamide within the UVB action spectrum.
Sasada K; Sakabe J; Tamura A; Kasuya A; Shimauchi T; Ito T; Hirakawa S; Tokura Y
Eur J Dermatol; 2012; 22(3):402-3. PubMed ID: 22503957
[No Abstract] [Full Text] [Related]
11. Editorial comment. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Garnick MB
BJU Int; 2012 Oct; 110(8):1155. PubMed ID: 22369480
[No Abstract] [Full Text] [Related]
12. Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer.
Lodde M; Lacombe L; Fradet Y
Urology; 2010 Nov; 76(5):1189-93. PubMed ID: 20303155
[TBL] [Abstract][Full Text] [Related]
13. Serial [
Boers J; Venema CM; de Vries EFJ; Hospers GAP; Boersma HH; Rikhof B; Dorbritz C; Glaudemans AWJM; Schröder CP
Eur J Cancer; 2021 Feb; 144():151-161. PubMed ID: 33341447
[TBL] [Abstract][Full Text] [Related]
14. A dramatic, objective antiandrogen withdrawal response: case report and review of the literature.
Lau YK; Chadha MK; Litwin A; Trump DL
J Hematol Oncol; 2008 Nov; 1():21. PubMed ID: 18986533
[TBL] [Abstract][Full Text] [Related]
15. Bicalutamide Monotherapy With Radiation Therapy for Localized Prostate Cancer: A Non-Evidence-Based Alternative.
Jia AY; Spratt DE
Int J Radiat Oncol Biol Phys; 2022 Jun; 113(2):316-319. PubMed ID: 35569476
[No Abstract] [Full Text] [Related]
16. Anti-androgen for myoepithelial tumor: a potent therapy yet a potential misleader.
Hijab A; Taha T; Charas T; Bar-Sela G; Stein P; Agbarya A
Anticancer Drugs; 2022 Jan; 33(1):e747-e751. PubMed ID: 34387605
[TBL] [Abstract][Full Text] [Related]
17. Bicalutamide.
Prescrire Int; 2007 Apr; 16(88):67. PubMed ID: 17458049
[TBL] [Abstract][Full Text] [Related]
18. Signet-ring cell/histiocytoid carcinoma of the eyelid: a case report and review of the literature.
Tanboon J; Uiprasertkul M; Luemsamran P
Am J Dermatopathol; 2013 Feb; 35(1):e1-5. PubMed ID: 22885554
[TBL] [Abstract][Full Text] [Related]
19. Structural basis for antagonism and resistance of bicalutamide in prostate cancer.
Bohl CE; Gao W; Miller DD; Bell CE; Dalton JT
Proc Natl Acad Sci U S A; 2005 Apr; 102(17):6201-6. PubMed ID: 15833816
[TBL] [Abstract][Full Text] [Related]
20. Primary signet ring cell carcinoma of the eyelid in a young woman.
Khoramnia R; Mayer C; Glaser E; Weirich G
Eye (Lond); 2011 Oct; 25(10):1380-2. PubMed ID: 21738227
[No Abstract] [Full Text] [Related]
[Next] [New Search]